BNHL-2015 for Children or Adolescents in China (NCT02405676) | Clinical Trial Compass
Active — Not RecruitingPhase 2/3
BNHL-2015 for Children or Adolescents in China
China200 participantsStarted 2015-01-01
Plain-language summary
The purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with the historical study CCCG-NHL-2010.
Who can participate
Age range16 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histology or cytologically confirmed matureB-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
* Able to comply with scheduled follow-up and with management of toxicity
* Signed informed consent
Exclusion Criteria:
* Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
* Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
* -Evidence of pregnancy or lactation period.
* Past or current anti-cancer treatment except corticosteroids during less than one week.
Exclusion criteria related to rituximab:
* Tumor cell negative for CD20.
* Prior exposure to rituximab.
* Hepatitis B carrier status history of HBV or positive serology.